Original Article

You have full text access to this OnlineOpen article

Prognostic value of P53, MDM-2, and MUC-1 for patients with inflammatory breast carcinoma†

  1. Erika Resetkova M.D.1,
  2. Ana M. Gonzalez-Angulo M.D.2,
  3. Nour Sneige M.D.1,
  4. Timothy J. Mcdonnell M.D.1,
  5. Aman U. Buzdar M.D.2,
  6. Shu Wan Kau R.N.2,
  7. Yuko Yamamura M.S.3,
  8. James M. Reuben Ph.D.1,
  9. Gabriel N. Hortobagyi M.D.2,
  10. Massimo Cristofanilli M.D.2,‡,*

Article first published online: 27 JUL 2004

DOI: 10.1002/cncr.20465

Issue

Cancer

Cancer

Volume 101, Issue 5, pages 913–917, 1 September 2004

Additional Information

How to Cite

Resetkova, E., Gonzalez-Angulo, A. M., Sneige, N., Mcdonnell, T. J., Buzdar, A. U., Kau, S. W., Yamamura, Y., Reuben, J. M., Hortobagyi, G. N. and Cristofanilli, M. (2004), Prognostic value of P53, MDM-2, and MUC-1 for patients with inflammatory breast carcinoma. Cancer, 101: 913–917. doi: 10.1002/cncr.20465

Author Information

  1. 1

    Department of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

  2. 2

    Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

  3. 3

    Department of Epidemiology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

  1. ‡

    Fax: (713) 794-4385

*Department of Breast Medical Oncology, Unit 424, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030-4009

  1. †

    Presented at the Fifteenth International Congress on Anti-Cancer Treatment, Paris, France, February 9–12, 2004.

  2. ‡

    Fax: (713) 794-4385

Publication History

  1. Issue published online: 18 AUG 2004
  2. Article first published online: 27 JUL 2004
  3. Manuscript Revised: 1 JUN 2004
  4. Manuscript Accepted: 1 JUN 2004
  5. Manuscript Received: 29 APR 2004

Funded by

  • Nellie B. Connally Breast Cancer Research Fund

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (159K)

Keywords:

  • P53;
  • MDM-2;
  • MUC-1;
  • prognosis;
  • inflammatory breast carcinoma

Abstract

BACKGROUND

Inflammatory breast carcinoma (IBC) is a rare and aggressive malignancy. Therapy for patients with IBC is multidisciplinary, and response to preoperative chemotherapy is considered an important predictor of outcome. Although only a limited number of molecular markers have been investigated in this setting, none has exhibited prognostic value for patients with IBC.

METHODS

Immunohistochemical assays for P53, MDM-2, and MUC-1 were performed retrospectively to evaluate potential correlations between these markers and pathologic response, time to progression (TTP), and overall survival (OS) in 19 patients with IBC.

RESULTS

After a median follow-up period of 46 months, patients with tumors that overexpressed P53 and did not express MUC-1 had a significantly shorter median TTP and median OS compared with other patients.

CONCLUSIONS

Expression of P53 and MUC-1 may be predictive of treatment efficacy and outcome for patients with IBC. Furthermore, these two markers may represent novel therapeutic targets in such patients. Cancer 2004. © 2004 American Cancer Society.

View Full Article (HTML) Get PDF (159K)